1103738-20-0

Basic information

• Product Name: Morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylate
• Synonyms: Morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylate;morpholine salt;(3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylic acid morpholine salt
• CAS NO: 1103738-20-0
• Molecular Formula: C12H21NO7
• Molecular Weight: 291.3
• Mol File: 1103738-20-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylate(1103738-20-0)
• EPA Substance Registry System: Morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylate(1103738-20-0)

Safety Data

• Hazardous Substances Data: 1103738-20-0(Hazardous Substances Data)

Upstream product

• 110-91-8 morpholine 
• 1103738-17-5 (3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxolane-5-carboxylic acid 
• 87-72-9 L-xylopyranose 
• 131156-47-3 (3aS,3bR,7aS,8aS)-2,2,5,5-tetramethyltetrahydro-3aH-[1,3]dioxolo[4',5':4,5]furo[3,2-d][1,3]dioxane 
• 609-06-3 L-xylose 
• 114861-22-2 1,2-O-isopropylidene-α-L-xylofuranose 

Downstream Products

• 1103738-19-7 ((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(morpholin-4-yl)methanone 
• 1103738-30-2 (4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuran[2,3-d][1,3]dioxolan-5-yl)methanone 

Relevant articles and documents

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.

SOLID FORMS OF (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL AND METHODS OF THEIR USE

Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.